4.3 Article

Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency

期刊

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
卷 50, 期 3, 页码 347-354

出版社

TAYLOR & FRANCIS LTD
DOI: 10.3109/00365521.2014.985707

关键词

adrenal insufficiency; apolipoprotein AI; cirrhosis; HDL cholesterol

向作者/读者索取更多资源

Backgrounds and aims: Adrenal insufficiency (AI) has been reported in patients with stable cirrhosis. A lack of substrates has been suggested as a possible contributing pathogenic mechanism leading to glucocorticoid deficiency in these subjects. To better explore this hypothesis, we studied lipoproteins in cirrhotics with and without AI. Methods. A total of 81 cirrhotic patients and 30 normal volunteers were enrolled. The severity of liver disease was graded by Child-Pugh score. Total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride (TG), and apolipoprotein AI (Apo-AI) levels were evaluated. HDL subfractions were measured by gradient gel electrophoresis. Adrenal function was assessed by the Low-Dose Short Synacthen Test. Results. Cirrhotic patients showed a significant reduction of TC, HDL, LDL, TG, and Apo-AI levels compared with controls. HDL3 was significantly lower, while HDL2 was higher, in cirrhotics compared with the controls. AI was observed in 26 patients. TC, TG, HDL, and Apo-AI were significantly reduced in cirrhotics with AI compared with those with normal adrenal function. HDL2 and HDL3 did not differ between these two groups. Delta cortisol was related to TC (r = 0.30, p < 0.01), TG (r = 0.22, p = 0.05), and Apo-AI (r = 0.37, p < 0.001). Multivariate analysis revealed that Apo-AI and HDL were independently associated with AI. Conclusion. Our study shows that TC, TG, HDL, and Apo-AI are reduced in cirrhotics with AI. In particular, because both HDL and Apo-AI play a primary role in providing substrates for steroidogenesis to adrenal cells, this deficiency may contribute to the pathogenesis of AI in these patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Peripheral Vascular Disease

APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism

Antonina Giammanco, Rossella Spina, Angelo B. Cefalu, Maurizio Averna

Summary: This review summarizes the different functions of Apolipoprotein C-III (ApoC-III) and highlights its multifaceted pathophysiological role. ApoC-III plays an important role in HDL metabolism and the development of atherosclerosis, inflammation, and ER stress. It is also linked to cardiovascular disease risk and progression of coronary artery disease, and recent clinical trials suggest that inhibiting ApoC-III may be a promising approach for managing hypertriglyceridemia and preventing cardiovascular disease.

CURRENT ATHEROSCLEROSIS REPORTS (2023)

Editorial Material Cardiac & Cardiovascular Systems

Lp(a): a genetic cause of clinical FH in children

Maurizio R. Averna, Angelo B. Cefalu

EUROPEAN HEART JOURNAL (2023)

Article Medicine, General & Internal

Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients

Sebastiano Cicco, Marco D'Abbondanza, Marco Proietti, Vincenzo Zaccone, Chiara Pes, Federica Caradio, Massimo Mattioli, Salvatore Piano, Alberto Maria Marra, Alessandro Nobili, Pier Mannuccio Mannucci, Antonello Pietrangelo, Giorgio Sesti, Elena Buzzetti, Andrea Salzano, Antonio Cimellaro

Summary: This study investigated the determinants and outcomes of antihypertensive drug prescription in older hospitalized patients. The findings suggest that adherence to guideline-recommended antihypertensive treatment is associated with a lower risk of adverse clinical outcomes.

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2023)

Article Biochemistry & Molecular Biology

PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk

Pere Rehues, Josefa Girona, Montse Guardiola, Nuria Plana, Roberto Scicali, Salvatore Piro, Ovidio Muniz-Grijalvo, Jose Luis Diaz-Diaz, Lluis Recasens, Marta Pinyol, Roser Rosales, Yaiza Esteban, Nuria Amigo, Lluis Masana, Daiana Ibarretxe, Josep Ribalta

Summary: This study evaluated the effects of iPCSK9 on glycoproteins A, B, and F, and found that iPCSK9 therapy not only reduced LDL cholesterol, but also decreased 1H-NMR glycoprotein signals, which correlated with a decrease in triglycerides and apoC-III.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Cardiac & Cardiovascular Systems

2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

Marina Cuchel, Frederick J. Raal, Robert A. Hegele, Khalid Al-Rasadi, Marcello Arca, Maurizio Averna, Eric Bruckert, Tomas Freiberger, Daniel Gaudet, Mariko Harada-Shiba, Lisa C. Hudgins, Meral Kayikcioglu, Luis Masana, Klaus G. Parhofer, Jeanine E. Roeters van Lennep, Raul D. Santos, Erik S. G. Stroes, Gerald F. Watts, Albert Wiegman, Jane K. Stock, Lale S. Tokgoezoglu, Alberico L. Catapano, Kausik K. Ray

Summary: This 2023 statement provides updated clinical guidance for the management of homozygous familial hypercholesterolaemia (HoFH), including criteria for diagnosis, genetic testing interpretation, and treatment recommendations. The statement emphasizes the importance of considering both phenotype and genotype in the diagnosis of HoFH, with a LDL-C level >10 mmol/L (>400 mg/dL) being indicative of the condition. Combination therapy targeting LDL-C, including the use of novel therapies like proprotein convertase subtilisin/kexin type 9 inhibitors, is recommended to achieve LDL-C goals and reduce the need for lipoprotein apheresis. To improve HoFH care globally, the statement recommends the implementation of national screening programs, education to increase awareness, and management guidelines adapted to local healthcare systems.

EUROPEAN HEART JOURNAL (2023)

Article Medicine, General & Internal

Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register

Elena Succurro, Alessio Novella, Alessandro Nobili, Federica Giofre, Franco Arturi, Angela Sciacqua, Francesco Andreozzi, Antonello Pietrangelo, Giorgio Sesti

Summary: Diabetes is a growing health burden globally, especially among elderly individuals with the highest prevalence. This study aimed to evaluate the appropriateness and adherence to safety recommendations in glucose-lowering drug prescriptions for hospitalized elderly patients with diabetes. The findings revealed a high prevalence of inappropriate use of sulfonylureas in the prescription of anti-diabetes drugs.

INTERNAL AND EMERGENCY MEDICINE (2023)

Article Biochemistry & Molecular Biology

Identification of a New RNA and Protein Integrated Biomarker Panel Associated with Kidney Function Impairment in DKD: Translational Implications

Alessandra Scamporrino, Stefania Di Mauro, Agnese Filippello, Grazia Di Marco, Antonino Di Pino, Roberto Scicali, Maurizio Di Marco, Emanuele Martorana, Roberta Malaguarnera, Francesco Purrello, Salvatore Piro

Summary: Diabetic kidney disease (DKD) is a complication that significantly increases the risk of end-stage kidney disease and cardiovascular events. The identification of novel, highly sensitive, and specific early biomarkers to diagnose DKD and predict kidney function decline is crucial.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Nutrition & Dietetics

Controlling Nutritional Status (CONUT) Score as a Potential Prognostic Indicator of In-Hospital Mortality, Sepsis and Length of Stay in an Internal Medicine Department

Nicoletta Miano, Maurizio Di Marco, Salvatore Alaimo, Giuseppe Coppolino, Giuseppe L'Episcopo, Stefano Leggio, Roberto Scicali, Salvatore Piro, Francesco Purrello, Antonino Di Pino

Summary: The CONUT score, which represents poor nutritional status, has been shown to be an indicator of adverse outcomes. This retrospective study analyzed data from 369 patients, divided into four groups based on the CONUT score. In-hospital all-cause mortality, length of hospital stay, and the prevalence of sepsis increased with higher CONUT scores. The increased risk associated with a high CONUT score remained significant even after adjusting for confounders. These findings highlight the importance of CONUT scores in predicting short-term in-hospital outcomes and complications.

NUTRIENTS (2023)

Article Cardiac & Cardiovascular Systems

Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia

Elena Olmastroni, Marta Gazzotti, Maurizio Averna, Marcello Arca, Patrizia Tarugi, Sebastiano Calandra, Stefano Bertolini, Alberico L. Catapano, Manuela Casula

Summary: This study aimed to determine the prevalence of LPA risk variants in adult individuals with familial hypercholesterolemia (FH) in Italy. The study found that a portion of FH patients had high lp(a) levels, which could not be explained by monogenic or polygenic causes. It suggests the importance of measuring lp(a) levels in diagnosing FH and excluding other factors that may contribute to the phenotype before performing genetic tests.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2023)

Article Medicine, General & Internal

Is COVID-19 All That Glitters?

Salvatore Spampinato, Maurizio Di Marco, Luciano Mammolito, Alessia Scarfia, Maurizio Valastro, Stefania Di Mauro, Giosiana Bosco, Francesco Purrello, Salvatore Piro

Summary: Over the past three years, the Coronavirus-19 disease has emerged as a global health emergency, drawing significant attention from the international scientific community. Efforts have been focused on understanding and addressing the pandemic, leading to the discovery of new pathologies related to SARS-CoV-2, such as MIS-C and MIS-A. However, this heightened focus on COVID-19 may have inadvertently impacted the diagnosis of unrelated diseases, including rare conditions. This article describes the diagnostic process of a rare vasculitis in a young woman with a recent clinical history of SARS-CoV-2.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Medicine, General & Internal

Evaluation of high-density lipoprotein-bound long non-coding RNAs in subjects with familial hypercholesterolaemia

Roberto Scicali, Giosiana Bosco, Alessandra Scamporrino, Stefania Di Mauro, Agnese Filippello, Francesco Di Giacomo Barbagallo, Salvatore Spampinato, Chiara Pavanello, Alice Ossoli, Antonino Di Pino, Laura Calabresi, Francesco Purrello, Salvatore Piro

Summary: This study aimed to investigate the presence of long non-coding RNAs (lncRNAs) carried by high-density lipoprotein (HDL) in familial hypercholesterolaemia (FH) subjects and evaluate their associations with lipoproteins and pulse wave velocity (PWV). The results showed that HDL carried lncRNA HIF1A-AS2, LASER, and LEXIS, and HDL-lncRNA LEXIS was significantly associated with Lp(a) levels. Moreover, both Lp(a) and HDL-lncRNA LEXIS were associated with PWV.

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2023)

Article Biochemistry & Molecular Biology

An Uncharacterised lncRNA Coded by the ASAP1 Locus Is Downregulated in Serum of Type 2 Diabetes Mellitus Patients

Cristina Barbagallo, Michele Stella, Stefania Di Mauro, Alessandra Scamporrino, Agnese Filippello, Francesca Scionti, Maria Teresa Di Martino, Michele Purrello, Marco Ragusa, Francesco Purrello, Salvatore Piro

Summary: Diabetes mellitus (DM) is a complex disease characterized by high blood glucose levels. Type 2 Diabetes (T2D) is the most common form, affecting middle-aged or elderly individuals and its incidence is increasing among children and adults. This study analyzed the transcriptome of serum samples from T2D patients and identified a long non-coding RNA (lncRNA) as a potential diagnostic biomarker. The combination of this lncRNA with clinical parameters showed better diagnostic performance than the glycated haemoglobin test. Using this biomarker in clinical practice would improve the diagnosis and management of T2D patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Cardiac & Cardiovascular Systems

Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA)

Giulia Chiesa, Maria Grazia Zenti, Andrea Baragetti, Carlo M. Barbagallo, Claudio Borghi, Furio Colivicchi, Aldo P. Maggioni, Davide Noto, Matteo Pirro, Angela A. Rivellese, Tiziana Sampietro, Francesco Sbrana, Marcello Arca, Maurizio Averna, Alberico L. Catapano

Summary: Lp(a) plays a causal role in cardiovascular disease and measuring Lp(a) concentration can be used as an indicator of cardiovascular risk. The presence of apo(a) size polymorphism poses challenges in Lp(a) measurement, but new strategies are being developed to overcome this. Currently, reducing Lp(a) levels can mainly be achieved through plasma apheresis and the use of specific drugs.

NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2023)

暂无数据